Who might be right for Oxbryta?

Oxbryta® Patient Profile – not an actual patient.

Not an actual patient

Find appropriate sickle cell disease (SCD) patients based on your practice

Please select the most common characteristics of the patients with
SCD you treat to learn more

Currently taking hydroxyurea (HU) therapy

Age group

Maria is a patient who has similar characteristics
to the HOPE trial population.

Oxbryta® Patient Profile: Maria - not an actual patient

Not an actual patient

Maria

  • 30-year-old Hispanic female with SCD genotype HbSS
  • She works at a bank and is a busy mother of 2 children

Relevant past medical history:

  • Received 2 blood transfusions in the past year
  • History of 2 vaso-occlusive crises (VOCs) in the past year

Treatment of SCD:

  • Treated with HU, on maximum tolerated dose
  • Taking folic acid

Baseline lab workup:

  • Hb = 6.5 g/dL
  • Indirect bilirubin = 7.5 mg/dL
  • Reticulocytes = 12%

Jamie could be a potential patient because she has been treated with the max dose of HU and Oxbryta is indicated for patients as young as 12.

Oxbryta® Patient Profile: Jamie - not an actual patient

Not an actual patient

Jamie

  • 12-year-old African American female with SCD genotype HbSS
  • She likes to play soccer

Relevant past medical history:

  • Presented with 1 vaso-occlusive crisis (VOC) in the past year

Treatment of SCD:

  • Treated with HU, on maximum tolerated dose
  • Taking folic acid

Baseline lab workup:

  • Hb = 7.5 g/dL
  • Indirect bilirubin = 4.0 mg/dL
  • Reticulocytes = 9.0%

Henry has had >2 vaso-occlusive crises (VOCs) in the past year, like 58% of patients in the HOPE trial.

Oxbryta® Patient Profile: Henry - not an actual patient

Not an actual patient

Henry

  • 50-year-old African American male with SCD genotype HbSβ0 thalassemia
  • He works as a consultant traveling each week until 1 year ago

Relevant past medical history:

  • Cannot receive blood transfusions due to alloantibodies
  • History of 3 VOCs and 2 episodes of acute chest syndrome in the past year
  • Recently started an ACE inhibitor for diagnosis of proteinuria

Treatment of SCD:

  • Discontinued HU therapy 5 years ago due to work lifestyle and inability to adhere to frequent lab monitoring

Baseline lab workup:

  • Hb = 7.0 g/dL
  • Indirect bilirubin = 6.5 mg/dL
  • Reticulocytes = 10%

Gabriel's parents have busy work schedules, making frequent medical appointments challenging. The safety profile observed in pediatric
patients 12 to <17 years of age treated with Oxbryta was similar to that
seen in adult patients.

Oxbryta® Patient Profile: Gabriel - not an actual patient

Not an actual patient

Gabriel

  • Gabriel is a 14-year-old Hispanic male with SCD genotype HbSS
  • Both of Gabriel’s parents have busy work schedules, making it challenging to bring him in for frequent medical appointments
  • He often spends his free time playing video games and watching TV

Relevant past medical history:

  • Presented with 3 VOCs in the past year
  • Established microalbuminuria and complains of yellowing in his eyes

Treatment of SCD:

  • Family refuses HU

Baseline lab workup:

  • Hb = 6.0 g/dL
  • Indirect bilirubin = 14 mg/dL
  • Reticulocytes = 5.5%
Oxbryta efficacy

Get the latest information about Oxbryta delivered to your inbox